Physician profile
Deelip Chatterjee
NPI 1790894707
$4,328.66
in general payments reported to CMS, 2019-2025
30 companies · $739 in 2025
The $739 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $964 · 2020: $194 · 2021: $539 · 2022: $613 · 2023: $640 · 2024: $640 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,018.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,634.53 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,054.27 | 2019-2025 | Breztri, Airsupra, Symbicort |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.05 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $159.48 | 2023-2025 | Opsumit |
| Amgen INC. | $155.17 | 2020-2024 | Evenity, Prolia, Tavneos |
| Pfizer INC. | $115.67 | 2023-2024 | |
| Radius Health, INC. | $105.74 | 2019-2025 | Tymlos |
| Insmed, INC. | $103.18 | 2024-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $81.89 | 2021-2025 | |
| Lilly USA, LLC | $56.59 | 2019-2025 | Zepbound |
| Avadel Cns Pharmaceuticals, LLC | $51.69 | 2024 | Lumryz |
| Philips North America LLC | $50.63 | 2019-2022 | |
| Genzyme Corporation | $44.58 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $42.48 | 2019 | |
| Viatris Specialty LLC | $38.16 | 2025 | Yupelri |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $34.00 | 2023 | Idacio |
| Novo Nordisk INC | $31.08 | 2022-2024 | Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $29.75 | 2023 | Sunosi |
| Regeneron Healthcare Solutions, INC. | $29.53 | 2022 | |
| Janssen Biotech, INC. | $29.19 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $27.62 | 2022 | |
| Exact Sciences Corporation | $23.99 | 2023 | Cologuard Collection Kit |
| 3b Medical, INC. | $23.26 | 2025 | Luna |
| Depuy Synthes Sales INC. | $22.64 | 2023 | Orthovisc |
| Ani Pharmaceuticals, INC. | $18.39 | 2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $16.04 | 2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $13.84 | 2022 | |
| Mylan Specialty L.P. | $13.61 | 2019 | |
| Mallinckrodt Hospital Products INC. | $13.53 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deelip Chatterjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.